Cleviprex is owned by Chiesi.
Cleviprex contains Clevidipine.
Cleviprex has a total of 3 drug patents out of which 0 drug patents have expired.
Cleviprex was authorised for market use on 01 August, 2008.
Cleviprex is available in emulsion;intravenous dosage forms.
The generics of Cleviprex are possible to be released after 10 October, 2031.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11103490 | CHIESI | Clevidipine emulsion formulations containing antimicrobial agents |
Oct, 2031
(8 years from now) | |
US10010537 | CHIESI | Clevidipine emulsion formulations containing antimicrobial agents |
Oct, 2031
(8 years from now) | |
US8658676 | CHIESI | Clevidipine emulsion formulations containing antimicrobial agents |
Oct, 2031
(8 years from now) |
Drugs and Companies using CLEVIDIPINE ingredient
Market Authorisation Date: 01 August, 2008
Treatment: NA
Dosage: EMULSION;INTRAVENOUS
6
United States
3
Japan
2
Mexico
2
Korea, Republic of
1
Canada
1
Brazil
1
China
1
Australia
1
New Zealand
1
EA
1
Denmark
1
Portugal
1
Hungary
1
Spain
1
Poland
1
Hong Kong
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic